Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation
| العنوان: | Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation |
|---|---|
| المؤلفون: | Christine Volk, Christopher G. King, Onder Alpdogan, Gabrielle L. Goldberg, Odette M. Smith, Sydney X. Lu, Miguel-Angel Perales, Robert R. Jenq, Marcel R.M. van den Brink, Nury L. Yim, David Suh, Lucy W. Kappel, Amanda M. Holland, Uttam K. Rao, Adi Diab, Jedd D. Wolchok, Alan N. Houghton, Il-Kang Na, Olaf Penack, Johannes L. Zakrzewski |
| المصدر: | Blood. 113:1574-1580 |
| بيانات النشر: | American Society of Hematology, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Fibroblast Growth Factor 7, medicine.medical_treatment, Immunology, Thymus Gland, CD8-Positive T-Lymphocytes, Biology, Cancer Vaccines, T-Lymphocytes, Regulatory, Biochemistry, DNA vaccination, Mice, chemistry.chemical_compound, Immune system, Interferon, Vaccines, DNA, medicine, Animals, Transplantation, Homologous, Lymphocyte Count, Bone Marrow Transplantation, Transplantation Chimera, Transplantation, Forkhead Transcription Factors, Cell Biology, Hematology, Immunotherapy, Mice, Inbred C57BL, Survival Rate, surgical procedures, operative, medicine.anatomical_structure, chemistry, CD4 Antigens, Female, Keratinocyte growth factor, Bone marrow, Stem cell, Immunologic Memory, Cell Division, CD8, Plasmids, medicine.drug |
| الوصف: | Keratinocyte growth factor (KGF), which is given exogenously to allogeneic bone marrow transplantation (allo-BMT) recipients, supports thymic epithelial cells and increases thymic output of naive T cells. Here, we demonstrate that this improved T-cell reconstitution leads to enhanced responses to DNA plasmid tumor vaccination. Tumor-bearing mice treated with KGF and DNA vaccination have improved long-term survival and decreased tumor burden after allo-BMT. When assayed before vaccination, KGF-treated allo-BMT recipients have increased numbers of peripheral T cells, including CD8+ T cells with vaccine-recognition potential. In response to vaccination, KGF-treated allo-BMT recipients, compared with control subjects, generate increased numbers of tumor-specific CD8+ cells, as well as increased numbers of CD8+ cells producing interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). We also found unanticipated benefits to antitumor immunity with the administration of KGF. KGF-treated allo-BMT recipients have an improved ratio of T effector cells to regulatory T cells, a larger fraction of effector cells that display a central memory phenotype, and effector cells that are derived from a broader T-cell–receptor repertoire. In conclusion, our data suggest that KGF can function as a potent vaccine adjuvant after allo-BMT through its effects on posttransplantation T-cell reconstitution. |
| تدمد: | 1528-0020 0006-4971 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d575bcf8ca3ea3ba1da0c1e7cf7b0dce https://doi.org/10.1182/blood-2008-05-155697 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....d575bcf8ca3ea3ba1da0c1e7cf7b0dce |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|